Log in

Relevant bibliographies by topics / Cancer ratio plus / Journal articles

To see the other types of publications on this topic, follow the link: Cancer ratio plus.

Journal articles on the topic 'Cancer ratio plus'

Author: Grafiati

Published: 2 June 2025

Last updated: 31 July 2025

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the top 50 journal articles for your research on the topic 'Cancer ratio plus.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Browse journal articles on a wide variety of disciplines and organise your bibliography correctly.

1

International, Journal of Medical Science and Innovative Research (IJMSIR). "A Cross Sectional Study to Determine The Efficacy of Serum LDH: Pleural Fluid Ada Ratio As A Biomarker of Malignant Pleural Effusion in IRD, SMS Medical College, Jaipur." International Journal of Medical Science and Innovative Research (IJMSIR) 9, no. 4 (2024): 151–58. https://doi.org/10.5281/zenodo.15422923.

Full text

Abstract:

<strong>Abstract</strong> <strong>Introduction</strong>: The malignant pleural effusion is one of the most common causes of exudative pleural effusion. There is no accurate and commonly accepted biochemical marker of MPE, hence using common parameters two ratio serum LDH: pleural fluid ADA (cancer ratio) and cancer ratio: pleural fluid lymphocyte count (cancer ratio plus) derived and their efficacy in identification of MPE is studied. <strong>Methods</strong>: 60 undiagnosed pleural effusion patients were studied in a hospital based cross sectional observational analytical study. The values of

APA, Harvard, Vancouver, ISO, and other styles

2

Verma, Akash, Rucha S. Dagaonkar, Dominic Marshall, John Abisheganaden, and R. W. Light. "Differentiating Malignant from Tubercular Pleural Effusion by Cancer Ratio Plus (Cancer Ratio: Pleural Lymphocyte Count)." Canadian Respiratory Journal 2016 (2016): 1–6. http://dx.doi.org/10.1155/2016/7348239.

Full text

Abstract:

Background. We performed prospective validation of the cancer ratio (serum LDH : pleural ADA ratio), previously reported as predictive of malignant effusion retrospectively, and assessed the effect of combining it with “pleural lymphocyte count” in diagnosing malignant pleural effusion (MPE).Methods. Prospective cohort study of patients hospitalized with lymphocyte predominant exudative pleural effusion in 2015.Results. 118 patients, 84 (71.2%) having MPE and 34 (28.8%) having tuberculous pleural effusion (TPE), were analysed. In multivariate logistic regression analysis, cancer ratio, serum L

APA, Harvard, Vancouver, ISO, and other styles

3

Eruku, Dr Baburao. "Differentiating malignant effusions from other exudative effusions by cancer ratio and cancer ratio plus." International Journal of Advanced Research in Medicine 3, no. 2 (2021): 525–29. http://dx.doi.org/10.22271/27069567.2021.v3.i2h.453.

Full text

APA, Harvard, Vancouver, ISO, and other styles

4

Subhankar Saren, Animesh Mandal, Amit Kumar Das, Ranjit Kumar Haldar, and Sudipta Pandit. "Identifying malignant pleural effusion from tubercular pleural effusion by study of cancer ratio and cancer ratio plus." Asian Journal of Medical Sciences 16, no. 2 (2025): 97–102. https://doi.org/10.71152/ajms.v16i2.4323.

Full text

Abstract:

Background: Early detection of malignant pleural effusions (MPE) through routine biochemical tests will go a long way in improving morbidity and mortality of these patients. Aims and Objectives: The current study was aimed to observe the usefulness of cancer ratio (CR) and CR plus to diagnose malignant effusions early in disease evolution. Materials and Methods: The study was a cross-sectional comparative observational study conducted at the indoor and outdoor facility of Respiratory Medicine department of Institute of Post Graduate Medical Education and Research, Kolkata. Results: Sixty-one p

APA, Harvard, Vancouver, ISO, and other styles

5

Wang, Jing-Houng, Yen-Yang Chen, Kwong-Ming Kee, et al. "The Prognostic Value of Neutrophil-to-Lymphocyte Ratio and Platelet-to-Lymphocyte Ratio in Patients with Hepatocellular Carcinoma Receiving Atezolizumab Plus Bevacizumab." Cancers 14, no. 2 (2022): 343. http://dx.doi.org/10.3390/cancers14020343.

Full text

Abstract:

Atezolizumab plus bevacizumab has been approved as the first-line systemic treatment for patients with unresectable hepatocellular carcinoma (uHCC). This study was designed to assess the clinical impact of atezolizumab plus bevacizumab in uHCC patients. A total of 48 uHCC patients receiving atezolizumab plus bevacizumab were identified, including first-line, second-line, third-line, and later-line settings. In these patients, the median progression-free survival (PFS) was 5.0 months, including 5.0 months for the first-line treatment, not reached for the second-line treatment, and 2.5 months fo

APA, Harvard, Vancouver, ISO, and other styles

6

Simon, Michael S., Rowan T. Chlebowski, Jean Wactawski-Wende, et al. "Estrogen Plus Progestin and Colorectal Cancer Incidence and Mortality." Journal of Clinical Oncology 30, no. 32 (2012): 3983–90. http://dx.doi.org/10.1200/jco.2012.42.7732.

Full text

Abstract:

Purpose During the intervention phase in the Women's Health Initiative (WHI) clinical trial, use of estrogen plus progestin reduced the colorectal cancer diagnosis rate, but the cancers were found at a substantially higher stage. To assess the clinical relevance of the findings, analyses of the influence of combined hormone therapy on colorectal cancer incidence and colorectal cancer mortality were conducted after extended follow-up. Patients and Methods The WHI study was a randomized, double-blind, placebo-controlled clinical trial involving 16,608 postmenopausal women with an intact uterus w

APA, Harvard, Vancouver, ISO, and other styles

7

Slamon, Dennis J., Patrick Neven, Stephen Chia, et al. "Phase III Randomized Study of Ribociclib and Fulvestrant in Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Advanced Breast Cancer: MONALEESA-3." Journal of Clinical Oncology 36, no. 24 (2018): 2465–72. http://dx.doi.org/10.1200/jco.2018.78.9909.

Full text

Abstract:

Purpose This phase III study evaluated ribociclib plus fulvestrant in patients with hormone receptor–positive/human epidermal growth factor receptor 2–negative advanced breast cancer who were treatment naïve or had received up to one line of prior endocrine therapy in the advanced setting. Patients and Methods Patients were randomly assigned at a two-to-one ratio to ribociclib plus fulvestrant or placebo plus fulvestrant. The primary end point was locally assessed progression-free survival. Secondary end points included overall survival, overall response rate, and safety. Results A total of 48

APA, Harvard, Vancouver, ISO, and other styles

8

Zhao, Shu, Minhang Zhou, Peng Wang, et al. "Sorafenib, Lenvatinib, or Lenvatinib Combining PD-1 Inhibitors Plus TACE in Unresectable Hepatocellular Carcinoma: A Retrospective Analysis." Technology in Cancer Research & Treatment 21 (January 2022): 153303382211336. http://dx.doi.org/10.1177/15330338221133640.

Full text

Abstract:

Introduction: This retrospective study aimed to compare the efficacy and safety of transarterial chemoembolization plus lenvatinib and programmed death 1 (PD-1) inhibitors versus transarterial chemoembolization plus lenvatinib or sorafenib in patients with unresectable hepatocellular carcinoma. Methods: Consecutive patients with unresectable hepatocellular carcinoma who received transarterial chemoembolization plus lenvatinib and PD-1 inhibitors, lenvatinib, or sorafenib were retrospectively identified in our institution between January 2018 and August 2020. The primary endpoint was overall su

APA, Harvard, Vancouver, ISO, and other styles

9

Bae, Soong June, Chang-Ik Yoon, So Eun Park, et al. "A neutrophil to lymphocyte ratio is predictive of response to neoadjuvant HER2-targeted therapies in the patients with HER2-positive breast cancer." Journal of Clinical Oncology 37, no. 15_suppl (2019): 587. http://dx.doi.org/10.1200/jco.2019.37.15_suppl.587.

Full text

Abstract:

587 Background: The neutrophil to lymphocyte ratio (NLR) has been reported that is associated with response to treatment and prognosis in breast cancer, but its role is unclear in HER2 positive breast cancer. In this study, the relevance of NLR for treatment efficacy was analyzed in HER2 positive breast cancer patients underwent neoadjuvant therapy. Methods: Pre-treatment NLR was assessed in 546 HER2 positive breast cancer patients divided into three groups according to neoadjuvant treatment regimens: i) chemotherapy alone, ii) chemotherapy plus trastuzumab, and iii) chemotherapy plus trastuzu

APA, Harvard, Vancouver, ISO, and other styles

10

Reck, Martin, Alexander Luft, Aleksandra Szczesna, et al. "Phase III Randomized Trial of Ipilimumab Plus Etoposide and Platinum Versus Placebo Plus Etoposide and Platinum in Extensive-Stage Small-Cell Lung Cancer." Journal of Clinical Oncology 34, no. 31 (2016): 3740–48. http://dx.doi.org/10.1200/jco.2016.67.6601.

Full text

Abstract:

Purpose Patients with extensive-stage disease small-cell lung cancer (SCLC) have poor survival outcomes despite first-line chemotherapy with etoposide and platinum. This randomized, double-blind phase III study evaluated the efficacy and safety of ipilimumab or placebo plus etoposide and platinum in patients with newly diagnosed extensive-stage disease SCLC. Patients and Methods Patients were randomly assigned at a ratio of one to one to receive chemotherapy with etoposide and platinum (cisplatin or carboplatin) plus ipilimumab 10 mg/kg or placebo every 3 weeks for a total of four doses each i

APA, Harvard, Vancouver, ISO, and other styles

11

Chen, Yun, Jinjun Ye, Zhengfei Zhu, et al. "Comparing Paclitaxel Plus Fluorouracil Versus Cisplatin Plus Fluorouracil in Chemoradiotherapy for Locally Advanced Esophageal Squamous Cell Cancer: A Randomized, Multicenter, Phase III Clinical Trial." Journal of Clinical Oncology 37, no. 20 (2019): 1695–703. http://dx.doi.org/10.1200/jco.18.02122.

Full text

Abstract:

PURPOSE This trial aimed to assess the efficacy and safety of the paclitaxel plus fluorouracil regimen versus the cisplatin plus fluorouracil regimen in definitive concurrent chemoradiotherapy (dCRT) in patients with locally advanced esophageal squamous cell carcinoma (ESCC). PATIENTS AND METHODS Patients with locally advanced ESCC were enrolled and randomly assigned to either the paclitaxel plus fluorouracil group or the cisplatin plus fluorouracil group. The patients in the paclitaxel plus fluorouracil group were treated with paclitaxel and fluorouracil one cycle per week in dCRT for five cy

APA, Harvard, Vancouver, ISO, and other styles

12

Hatfield, Laura A., Haiden A. Huskamp, and Elizabeth B. Lamont. "Survival and Toxicity After Cisplatin Plus Etoposide Versus Carboplatin Plus Etoposide for Extensive-Stage Small-Cell Lung Cancer in Elderly Patients." Journal of Oncology Practice 12, no. 7 (2016): 666–73. http://dx.doi.org/10.1200/jop.2016.012492.

Full text

Abstract:

Purpose: Elderly patients with cancer are under-represented in clinical trials and risk greater toxicity from chemotherapy. These patients and their physicians need better evidence to decide among guideline-recommended regimens. We test whether patients with extensive-stage small-cell lung cancer (ES SCLC) have noninferior survival and less hospital-based health care after carboplatin/etoposide compared with cisplatin/etoposide. Methods: We analyzed SEER-Medicare data for beneficiaries with ES SCLC diagnosed at age 67 years and older between 1995 and 2009. Among patients treated with first-lin

APA, Harvard, Vancouver, ISO, and other styles

13

Jiang, Wei, Zhichao He, Tiantian Zhang, et al. "Cost–effectiveness analysis of ribociclib plus fulvestrant for hormone receptor-positive/human EGF receptor 2-negative breast cancer." Immunotherapy 13, no. 8 (2021): 661–68. http://dx.doi.org/10.2217/imt-2020-0237.

Full text

Abstract:

Aim: To evaluate the cost–effectiveness of ribociclib plus fulvestrant versus fulvestrant in hormone receptor-positive/human EGF receptor 2-negative advanced breast cancer. Materials & methods: A three-state Markov model was developed to evaluate the costs and effectiveness over 10 years. Direct costs and utility values were obtained from previously published studies. We calculated incremental cost–effectiveness ratio to evaluate the cost–effectiveness at a willingness-to-pay threshold of $150,000 per additional quality-adjusted life year. Results: The incremental cost–effectiveness ratio

APA, Harvard, Vancouver, ISO, and other styles

14

Ryan, Christopher W., Ofer Merimsky, Mark Agulnik, et al. "PICASSO III: A Phase III, Placebo-Controlled Study of Doxorubicin With or Without Palifosfamide in Patients With Metastatic Soft Tissue Sarcoma." Journal of Clinical Oncology 34, no. 32 (2016): 3898–905. http://dx.doi.org/10.1200/jco.2016.67.6684.

Full text

Abstract:

Purpose Palifosfamide is the active metabolite of ifosfamide and does not require prodrug activation, thereby avoiding the generation of toxic metabolites. The PICASSO III trial compared doxorubicin plus palifosfamide with doxorubicin plus placebo in patients who had received no prior systemic therapy for metastatic soft tissue sarcoma. Patients and Methods Patients were randomly assigned 1:1 to receive doxorubicin 75 mg/m2 intravenously day 1 plus palifosfamide 150 mg/m2/d intravenously days 1 to 3 or doxorubicin plus placebo once every 21 days for up to six cycles. The primary end point was

APA, Harvard, Vancouver, ISO, and other styles

15

Giuliani, Jacopo, Beatrice Mantoan, and Andrea Bonetti. "Cost-effectiveness of encorafenib plus cetuximab in BRAF V600E-mutated colorectal cancer." Journal of Oncology Pharmacy Practice 28, no. 1 (2021): 199–202. http://dx.doi.org/10.1177/10781552211045006.

Full text

Abstract:

Recently, the introduction of encorafenib in combination with cetuximab was considered as a practice changing in BRAFV600-mutated metastatic colorectal cancer. The aim of this paper was to assess the cost-effectiveness of encorafenib plus cetuximab in the second-line treatment of BRAFV600-mutated metastatic colorectal cancer. BEACON CRC Trail was considered. Incremental cost-effectiveness ratio was calculated as the ratio between the difference of the costs in the intervention and in the control groups (pharmacy costs) and the difference between the effect in the intervention and in the contro

APA, Harvard, Vancouver, ISO, and other styles

16

Shitara, Kohei, Jaffer A. Ajani, Markus Moehler, et al. "Nivolumab plus chemotherapy or ipilimumab in gastro-oesophageal cancer." Nature 603, no. 7903 (2022): 942–48. http://dx.doi.org/10.1038/s41586-022-04508-4.

Full text

Abstract:

AbstractStandard first-line chemotherapy results in disease progression and death within one year in most patients with human epidermal growth factor receptor 2 (HER2)-negative gastro-oesophageal adenocarcinoma1–4. Nivolumab plus chemotherapy demonstrated superior overall survival versus chemotherapy at 12-month follow-up in gastric, gastro-oesophageal junction or oesophageal adenocarcinoma in the randomized, global CheckMate 649 phase 3 trial5 (programmed death ligand-1 (PD-L1) combined positive score ≥5 and all randomized patients). On the basis of these results, nivolumab plus chemotherapy

APA, Harvard, Vancouver, ISO, and other styles

17

Warner, Ellen, Siqi Zhu, Donald B. Plewes, et al. "Breast Cancer Mortality among Women with a BRCA1 or BRCA2 Mutation in a Magnetic Resonance Imaging Plus Mammography Screening Program." Cancers 12, no. 11 (2020): 3479. http://dx.doi.org/10.3390/cancers12113479.

Full text

Abstract:

Annual breast magnetic resonance imaging (MRI) plus mammography is the standard of care for screening women with inherited BRCA1/2 mutations. However, long-term breast cancer-related mortality with screening is unknown. Between 1997 and June 2011, 489 previously unaffected BRCA1/2 mutation carriers aged 25 to 65 years were screened with annual MRI plus mammography on our study. Thereafter, participants were eligible to continue MRI screening through the high-risk Ontario Breast Screening Program. In 2019, our data were linked to the Ontario Cancer Registry of Cancer Care Ontario to identify al

APA, Harvard, Vancouver, ISO, and other styles

18

Monk, Bradley J., Thomas J. Herzog, Stanley B. Kaye, et al. "Trabectedin Plus Pegylated Liposomal Doxorubicin in Recurrent Ovarian Cancer." Journal of Clinical Oncology 28, no. 19 (2010): 3107–14. http://dx.doi.org/10.1200/jco.2009.25.4037.

Full text

Abstract:

PurposeThe objective of this study was to compare the efficacy and safety of trabectedin plus pegylated liposomal doxorubicin (PLD) with that of PLD alone in women with recurrent ovarian cancer after failure of first-line, platinum-based chemotherapy.Patients and MethodsWomen ≥ 18 years, stratified by performance status (0 to 1 v 2) and platinum sensitivity, were randomly assigned to receive an intravenous infusion of PLD 30 mg/m2followed by a 3-hour infusion of trabectedin 1.1 mg/m2every 3 weeks or PLD 50 mg/m2every 4 weeks. The primary end point was progression-free survival (PFS) by indepen

APA, Harvard, Vancouver, ISO, and other styles

19

Choi, Kwang Hyun, Chan Sub Park, Sang Hee Kim, et al. "Comparison of the Efficacy between First-Line Treatment Regimens for Patients with Hormone Receptor-Positive and HER2-Negative Metastatic Breast Cancer." Journal of Breast Disease 9, no. 2 (2021): 65–70. http://dx.doi.org/10.14449/jbd.2021.9.2.65.

Full text

Abstract:

Purpose: Endocrine therapy is the first-line treatment recommended for patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative metastatic breast cancer without visceral crisis. However, this recommendation has not been followed clinically because of efficacy issues. In this study, the survival of patients with HR-positive/HER2-negative metastatic breast cancer was evaluated based on the following first-line treatment regimens: the combination of palbociclib plus letrozole, conventional endocrine therapy, or chemotherapy.Methods: Medical records we

APA, Harvard, Vancouver, ISO, and other styles

20

Johnston, Stephen R. D., Roberto Hegg, Seock-Ah Im, et al. "Phase III, Randomized Study of Dual Human Epidermal Growth Factor Receptor 2 (HER2) Blockade With Lapatinib Plus Trastuzumab in Combination With an Aromatase Inhibitor in Postmenopausal Women With HER2-Positive, Hormone Receptor–Positive Metastatic Breast Cancer: Updated Results of ALTERNATIVE." Journal of Clinical Oncology 39, no. 1 (2021): 79–89. http://dx.doi.org/10.1200/jco.20.01894.

Full text

Abstract:

PURPOSE Human epidermal growth factor receptor 2 (HER2) targeting plus endocrine therapy (ET) improved clinical benefit in HER2-positive, hormone receptor (HR)–positive metastatic breast cancer (MBC) versus ET alone. Dual HER2 blockade enhances clinical benefit versus single HER2 blockade. The ALTERNATIVE study evaluated the efficacy and safety of dual HER2 blockade plus aromatase inhibitor (AI) in postmenopausal women with HER2-positive/HR-positive MBC who received prior ET and prior neo(adjuvant)/first-line trastuzumab (TRAS) plus chemotherapy. This updated article reflects minor numerical c

APA, Harvard, Vancouver, ISO, and other styles

21

Chen, Li, Ying Hao, Xiliang Cong, et al. "Peripheral Venous Blood Platelet-to-Lymphocyte Ratio (PLR) for Predicting the Survival of Patients With Gastric Cancer Treated With SOX or XELOX Regimen Neoadjuvant Chemotherapy." Technology in Cancer Research & Treatment 18 (January 1, 2019): 153303381982948. http://dx.doi.org/10.1177/1533033819829485.

Full text

Abstract:

Background: Inflammation plays an important role in tumor progression. Predicting survival is remarkably difficult in patients with gastric cancer receiving neoadjuvant chemotherapy. The aim of the present study is to investigate the potential prognostic significance of the platelet-to-lymphocyte ratio in patients with gastric cancer receiving S-1 plus oxaliplatin or oxaliplatin and capecitabine regimen. Methods: Ninety-one patients with gastric cancer treated with neoadjuvant chemotherapy were enrolled in this study and then underwent operation. The optimal cutoff value was calculated using r

APA, Harvard, Vancouver, ISO, and other styles

22

Taieb, Julien, Gerald W. Prager, Marwan Fakih, et al. "Effect of trifluridine/tipiracil in combination with bevacizumab on ECOG-PS in refractory metastatic colorectal cancer: An analysis of the phase 3 SUNLIGHT trial." Journal of Clinical Oncology 41, no. 16_suppl (2023): 3594. http://dx.doi.org/10.1200/jco.2023.41.16_suppl.3594.

Full text

Abstract:

3594 Background: SUNLIGHT, an international, open-label, randomized, phase 3 study comparing trifluridine/tipiracil (FTD/TPI) in combination with bevacizumab versus FTD/TPI monotherapy in patients with metastatic colorectal cancer (mCRC) met its primary endpoint (overall survival [OS]) and key secondary endpoint (progression free survival [PFS]). Primary and key secondary outcomes in patients with maintained ECOG-PS are reported. Methods: SUNLIGHT enrolled patients with ECOG-PS 0/1. ECOG-PS was evaluated at baseline, at each treatment cycle, and at withdrawal visit. Worst ECOG values and time

APA, Harvard, Vancouver, ISO, and other styles

23

van Hazel, Guy A., Volker Heinemann, Navesh K. Sharma, et al. "SIRFLOX: Randomized Phase III Trial Comparing First-Line mFOLFOX6 (Plus or Minus Bevacizumab) Versus mFOLFOX6 (Plus or Minus Bevacizumab) Plus Selective Internal Radiation Therapy in Patients With Metastatic Colorectal Cancer." Journal of Clinical Oncology 34, no. 15 (2016): 1723–31. http://dx.doi.org/10.1200/jco.2015.66.1181.

Full text

Abstract:

Purpose SIRFLOX was a randomized, multicenter trial designed to assess the efficacy and safety of adding selective internal radiation therapy (SIRT) using yttrium-90 resin microspheres to standard fluorouracil, leucovorin, and oxaliplatin (FOLFOX)–based chemotherapy in patients with previously untreated metastatic colorectal cancer. Patients and Methods Chemotherapy-naïve patients with liver metastases plus or minus limited extrahepatic metastases were randomly assigned to receive either modified FOLFOX (mFOLFOX6; control) or mFOLFOX6 plus SIRT (SIRT) plus or minus bevacizumab. The primary end

APA, Harvard, Vancouver, ISO, and other styles

24

Carvajal, Richard D., Sophie Piperno-Neumann, Ellen Kapiteijn, et al. "Selumetinib in Combination With Dacarbazine in Patients With Metastatic Uveal Melanoma: A Phase III, Multicenter, Randomized Trial (SUMIT)." Journal of Clinical Oncology 36, no. 12 (2018): 1232–39. http://dx.doi.org/10.1200/jco.2017.74.1090.

Full text

Abstract:

Purpose Uveal melanoma is the most common primary intraocular malignancy in adults with no effective systemic treatment option in the metastatic setting. Selumetinib (AZD6244, ARRY-142886) is an oral, potent, and selective MEK1/2 inhibitor with a short half-life, which demonstrated single-agent activity in patients with metastatic uveal melanoma in a randomized phase II trial. Methods The Selumetinib (AZD6244: ARRY-142886) (Hyd-Sulfate) in Metastatic Uveal Melanoma (SUMIT) study was a phase III, double-blind trial ( ClinicalTrial.gov identifier: NCT01974752) in which patients with metastatic u

APA, Harvard, Vancouver, ISO, and other styles

25

Bastos, Diogo Assed, Andrey Soares, Fabio Augusto Barros Schutz, et al. "Androgen Receptor Pathway Inhibitor Therapy for Advanced Prostate Cancer." JAMA Network Open 8, no. 1 (2025): e2454253. https://doi.org/10.1001/jamanetworkopen.2024.54253.

Full text

Abstract:

ImportanceThe open-label randomized phase 2 LACOG0415 trial evaluated 3 treatment strategies for patients with advanced castration-sensitive prostate cancer (CSPC): androgen deprivation therapy (ADT) plus abiraterone acetate and prednisone (AAP), apalutamide (APA) alone, or APA plus AAP.ObjectiveTo investigate the association of ADT plus AAP, APA alone, or APA plus AAP with health-related quality of life (HRQOL) in patients with advanced CSPC in the LACOG0415 trial.Design, Setting, and ParticipantsThe LACOG0415 randomized clinical trial comprised 128 patients with advanced CSPC who were random

APA, Harvard, Vancouver, ISO, and other styles

26

Kawabata, Ryohei, Daisuke Sakai, Shigenori Kadowaki, et al. "Subgroup analyses of the effect of ramucirumab in pretreatment with immune checkpoint inhibitor in RINDBeRG: A randomized clinical trial in third- or further-line treatment of gastric cancer." Journal of Clinical Oncology 42, no. 3_suppl (2024): 339. http://dx.doi.org/10.1200/jco.2024.42.3_suppl.339.

Full text

Abstract:

339 Background: To confirm synergistic effect of immune checkpoint blockade and anti-angiogenesis in cancer treatment, we evaluated the effect of pretreatment with immune checkpoint inhibitors to ramucirumab plus irinotecan versus irinotecan in the third or later line treatment beyond progression after ramucirumab for advanced gastric cancer from the RINDBeRG trial. Methods: Patients received ramucirumab at 8 mg/kg plus irinotecan at 150 mg/m2 or irinotecan alone. End points were compared between treatment arms and pretreatments with nivolumab (NIVO+, n = 226) or without nivolumab (NIVO-, n =

APA, Harvard, Vancouver, ISO, and other styles

27

Sathya, Jinka R., Ian R. Davis, Jim A. Julian, et al. "Randomized Trial Comparing Iridium Implant Plus External-Beam Radiation Therapy With External-Beam Radiation Therapy Alone in Node-Negative Locally Advanced Cancer of the Prostate." Journal of Clinical Oncology 23, no. 6 (2005): 1192–99. http://dx.doi.org/10.1200/jco.2005.06.154.

Full text

Abstract:

Purpose To determine if iridium implant (IM) and external-beam radiation therapy (EBRT) is better than standard EBRT in locally advanced prostate cancer. Methods Patients with T2 and T3 prostate cancer with no evidence of metastatic disease were randomly assigned to EBRT of 66 Gy in 33 fractions during 6.5 weeks or to IM of 35 Gy delivered to the prostate during 48 hours plus EBRT of 40 Gy in 20 fractions during 4 weeks. The primary outcome consisted of biochemical or clinical failure (BCF). BCF was defined by biochemical failure, clinical failure, or death as a result of prostate cancer. Seco

APA, Harvard, Vancouver, ISO, and other styles

28

Govindan, Ramaswamy, Aleksandra Szczesna, Myung-Ju Ahn, et al. "Phase III Trial of Ipilimumab Combined With Paclitaxel and Carboplatin in Advanced Squamous Non–Small-Cell Lung Cancer." Journal of Clinical Oncology 35, no. 30 (2017): 3449–57. http://dx.doi.org/10.1200/jco.2016.71.7629.

Full text

Abstract:

Purpose Patients with squamous non–small-cell lung cancer (NSCLC) have poor prognosis and limited treatment options. This randomized, double-blind, phase III study investigated the efficacy and safety of first-line ipilimumab or placebo plus paclitaxel and carboplatin in advanced squamous NSCLC. Patients and Methods Patients with stage IV or recurrent chemotherapy-naïve squamous NSCLC were randomly assigned (1:1) to receive paclitaxel and carboplatin plus blinded ipilimumab 10 mg/kg or placebo every 3 weeks on a phased induction schedule comprising six chemotherapy cycles, with ipilimumab or p

APA, Harvard, Vancouver, ISO, and other styles

29

Chen, Mifen, Zhenghang Wang, Zimin Liu, et al. "The Optimal Therapy after Progression on Immune Checkpoint Inhibitors in MSI Metastatic Gastrointestinal Cancer Patients: A Multicenter Retrospective Cohort Study." Cancers 14, no. 20 (2022): 5158. http://dx.doi.org/10.3390/cancers14205158.

Full text

Abstract:

Background: In microsatellite instability (MSI)/mismatch repair-deficient (dMMR) gastrointestinal cancers, the optimum therapy after the progression of immune checkpoint inhibitors (ICIs) is yet unknown. Here, we compared the efficacy of programmed death 1 (PD1)/programmed death ligand-1 (PD-L1) inhibitors plus other therapy and chemotherapy with or without targeted therapy in MSI/dMMR gastrointestinal cancer patients after progression on anti-PD1/PD-L1 monotherapy. Methods: We retrospectively recruited MSI/dMMR gastrointestinal cancer patients who had progressed on anti-PD1/PD-L1 monotherapy.

APA, Harvard, Vancouver, ISO, and other styles

30

Rao, Sheela, Francesco Sclafani, Cathy Eng, et al. "International Rare Cancers Initiative Multicenter Randomized Phase II Trial of Cisplatin and Fluorouracil Versus Carboplatin and Paclitaxel in Advanced Anal Cancer: InterAAct." Journal of Clinical Oncology 38, no. 22 (2020): 2510–18. http://dx.doi.org/10.1200/jco.19.03266.

Full text

Abstract:

PURPOSE To compare cisplatin plus fluorouracil (FU) versus carboplatin plus paclitaxel in chemotherapy-naïve advanced anal cancer to establish the optimal regimen. PATIENTS AND METHODS Patients who had not received systemic therapy for advanced anal cancer were randomly assigned 1:1 to intravenous cisplatin 60 mg/m2 (day 1) plus FU 1,000 mg/m2 (days 1-4) every 21 days or carboplatin (area under the curve, 5; day 1) plus paclitaxel 80 mg/m2 (days 1, 8, and 15) every 28 days for 24 weeks, until disease progression, intolerable toxicity, or withdrawal of consent. Primary end point was objective r

APA, Harvard, Vancouver, ISO, and other styles

31

Younes, Anas, Laurie H. Sehn, Peter Johnson, et al. "Randomized Phase III Trial of Ibrutinib and Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Non–Germinal Center B-Cell Diffuse Large B-Cell Lymphoma." Journal of Clinical Oncology 37, no. 15 (2019): 1285–95. http://dx.doi.org/10.1200/jco.18.02403.

Full text

Abstract:

PURPOSE Ibrutinib has shown activity in non–germinal center B-cell diffuse large B-cell lymphoma (DLBCL). This double-blind phase III study evaluated ibrutinib and rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in untreated non–germinal center B-cell DLBCL. PATIENTS AND METHODS Patients were randomly assigned at a one-to-one ratio to ibrutinib (560 mg per day orally) plus R-CHOP or placebo plus R-CHOP. The primary end point was event-free survival (EFS) in the intent-to-treat (ITT) population and the activated B-cell (ABC) DLBCL subgroup. Secondary end point

APA, Harvard, Vancouver, ISO, and other styles

32

Van Cutsem, Eric, Margaret A. Tempero, Darren Sigal, et al. "Randomized Phase III Trial of Pegvorhyaluronidase Alfa With Nab-Paclitaxel Plus Gemcitabine for Patients With Hyaluronan-High Metastatic Pancreatic Adenocarcinoma." Journal of Clinical Oncology 38, no. 27 (2020): 3185–94. http://dx.doi.org/10.1200/jco.20.00590.

Full text

Abstract:

PURPOSE To evaluate the efficacy and safety of pegvorhyaluronidase alfa (PEGPH20) plus nab-paclitaxel/gemcitabine (AG) in patients with hyaluronan-high metastatic pancreatic ductal adenocarcinoma (PDA). PATIENTS AND METHODS HALO 109-301 was a phase III, randomized, double-blind, placebo-controlled study. Patients ≥ 18 years of age with untreated, metastatic, hyaluronan-high PDA were randomly assigned 2:1 to PEGPH20 plus AG or placebo plus AG. Treatment was administered intravenously in 4-week cycles (3 weeks on, 1 week off) until progression or intolerable adverse events: PEGPH20 3.0 µg/kg twi

APA, Harvard, Vancouver, ISO, and other styles

33

Ishigami, Hironori, Yoshiyuki Fujiwara, Ryoji Fukushima, et al. "Phase III Trial Comparing Intraperitoneal and Intravenous Paclitaxel Plus S-1 Versus Cisplatin Plus S-1 in Patients With Gastric Cancer With Peritoneal Metastasis: PHOENIX-GC Trial." Journal of Clinical Oncology 36, no. 19 (2018): 1922–29. http://dx.doi.org/10.1200/jco.2018.77.8613.

Full text

Abstract:

Purpose Intraperitoneal paclitaxel plus systemic chemotherapy demonstrated promising clinical effects in patients with gastric cancer with peritoneal metastasis. We aimed to verify its superiority over standard systemic chemotherapy in overall survival. Patients and Methods This randomized phase III trial enrolled patients with gastric cancer with peritoneal metastasis who had received no or short-term (< 2 months) chemotherapy. Patients were randomly assigned at a two-to-one ratio to receive intraperitoneal and intravenous paclitaxel plus S-1 (IP; intraperitoneal paclitaxel 20 mg/m2 and in

APA, Harvard, Vancouver, ISO, and other styles

34

Wujanto, Caryn, Jeremy Tey, Balamurugan Vellayappan, et al. "Outcomes of oesophageal cancer treated with neoadjuvant compared with definitive chemoradiotherapy." Annals of the Academy of Medicine, Singapore 50, no. 7 (2021): 536–47. http://dx.doi.org/10.47102/annals-acadmedsg.2020633.

Full text

Abstract:

Introduction: We report outcomes of patients with oesophageal cancer treated with neoadjuvant chemoradiotherapy (NACRT) plus surgery or definitive chemoradiotherapy (chemoRT) at our institution. Methods: We retrospectively reviewed patients who underwent chemoRT from 2005 to 2017. The primary outcome was overall survival (OS). Secondary outcomes were disease-free survival (DFS) and toxicities. Results: We identified 96 patients with median age of 64 years and squamous cell carcinoma in 82.3%. Twenty-nine patients (30.2%) received NACRT plus surgery, 67 patients (69.8%) received definitive chem

APA, Harvard, Vancouver, ISO, and other styles

35

Gayaf, Mine, and Mustafa Canbaz. "Diagnostic Value of Cancer Ratio Plus Obtained by Dividing Cancer Ratio to Pleural Fluid Lymphocyte in Differentiation Malign Pleural Effusion from Tubercular Pleural Effusion." Turkish Thoracic Journal 20, no. -1 (2019): 6. http://dx.doi.org/10.5152/turkthoracj.2019.06.

Full text

APA, Harvard, Vancouver, ISO, and other styles

36

Mackey, John R., Manuel Ramos-Vazquez, Oleg Lipatov, et al. "Primary Results of ROSE/TRIO-12, a Randomized Placebo-Controlled Phase III Trial Evaluating the Addition of Ramucirumab to First-Line Docetaxel Chemotherapy in Metastatic Breast Cancer." Journal of Clinical Oncology 33, no. 2 (2015): 141–48. http://dx.doi.org/10.1200/jco.2014.57.1513.

Full text

Abstract:

Purpose Currently, antiangiogenic strategies in metastatic breast cancer have demonstrated modest improvements in progression-free survival (PFS) but not improved quality or duration of survival, warranting evaluation of new agents in a placebo-controlled setting. Ramucirumab is a human immunoglobulin G1 antibody that binds vascular endothelial growth factor receptor-2 and blocks ligand-stimulated activation. The ROSE/TRIO-012 trial evaluated ramucirumab with docetaxel in unresectable, locally recurrent, or metastatic breast cancer. Patients and Methods In this double-blind, placebo-controlled

APA, Harvard, Vancouver, ISO, and other styles

37

Fagot, J. P., S. Samson, J. Merlière, P. Gabach, and A. Fagot. "L’association fréquente des pathologies somatiques aux troubles psychiatriques en population adulte, à travers les données de l’Assurance Maladie." European Psychiatry 28, S2 (2013): 87. http://dx.doi.org/10.1016/j.eurpsy.2013.09.233.

Full text

Abstract:

Introduction.Les fréquences des pathologies somatiques chez les adultes atteints de maladies psychiatriques sont peu documentées.Méthodes.Les bénéficiaires du régime général de l’Assurance Maladie en 2010, âgés d’au moins 18 ans, pris en charge pour troubles psychiatriques ont été identifiés dans le SNIIRAM à partir des diagnostics liés aux :– affections de longue durée ;– hospitalisations (PMSI-MCO, SSR, RIM-P) ;– arrêts de travail et invalidité [1].Les maladies somatiques ont été déterminées à partir des diagnostics liés aux affections de longue durée et aux hospitalisations [1]. Les prévale

APA, Harvard, Vancouver, ISO, and other styles

38

Zamarin, Dmitriy, Robert A. Burger, Michael W. Sill, et al. "Randomized Phase II Trial of Nivolumab Versus Nivolumab and Ipilimumab for Recurrent or Persistent Ovarian Cancer: An NRG Oncology Study." Journal of Clinical Oncology 38, no. 16 (2020): 1814–23. http://dx.doi.org/10.1200/jco.19.02059.

Full text

Abstract:

PURPOSE Single-agent PD-1 blockade exhibits limited efficacy in epithelial ovarian cancer (EOC). We evaluated ipilimumab plus nivolumab compared with nivolumab alone in women with persistent or recurrent EOC. METHODS Eligibility criteria included measurable disease, 1-3 prior regimens, and platinum-free interval (PFI) < 12 months. Participants were randomly allocated to intravenous nivolumab (every 2 weeks) or induction with nivolumab plus ipilimumab for 4 doses (every 3 weeks), followed by every-2-week maintenance nivolumab for a maximum of 42 doses. The primary null hypothesis was equal p

APA, Harvard, Vancouver, ISO, and other styles

39

von Minckwitz, Gunter, Andreas du Bois, Marcus Schmidt, et al. "Trastuzumab Beyond Progression in Human Epidermal Growth Factor Receptor 2–Positive Advanced Breast Cancer: A German Breast Group 26/Breast International Group 03-05 Study." Journal of Clinical Oncology 27, no. 12 (2009): 1999–2006. http://dx.doi.org/10.1200/jco.2008.19.6618.

Full text

Abstract:

Purpose Trastuzumab shows clinical activity in human epidermal growth factor receptor 2 (HER-2)–positive early and advanced breast cancer. In the German Breast Group 26/Breast International Group 03-05 trial, we investigated if trastuzumab treatment should be continued beyond progression. Methods Patients with HER-2–positive breast cancer that progresses during treatment with trastuzumab were randomly assigned to receive capecitabine (2,500 mg/m2 body-surface area on days 1 through 14 [1,250 mg/m2 semi-daily]) alone or with continuation of trastuzumab (6 mg/kg body weight) in 3-week cycles. Th

APA, Harvard, Vancouver, ISO, and other styles

40

Ueno, Hideki, Tatsuya Ioka, Masafumi Ikeda, et al. "Randomized Phase III Study of Gemcitabine Plus S-1, S-1 Alone, or Gemcitabine Alone in Patients With Locally Advanced and Metastatic Pancreatic Cancer in Japan and Taiwan: GEST Study." Journal of Clinical Oncology 31, no. 13 (2013): 1640–48. http://dx.doi.org/10.1200/jco.2012.43.3680.

Full text

Abstract:

Purpose The present phase III study was designed to investigate the noninferiority of S-1 alone and superiority of gemcitabine plus S-1 compared with gemcitabine alone with respect to overall survival. Patients and Methods The participants were chemotherapy-naive patients with locally advanced or metastatic pancreatic cancer. Patients were randomly assigned to receive only gemcitabine (1,000 mg/m2 on days 1, 8, and 15 of a 28-day cycle), only S-1 (80, 100, or 120 mg/d according to body-surface area on days 1 through 28 of a 42-day cycle), or gemcitabine plus S-1 (gemcitabine 1,000 mg/m2 on day

APA, Harvard, Vancouver, ISO, and other styles

41

Wen, Lingling, and Hao Ma. "Effect of a combination of dexmedetomidine and either isoflurane or sevoflurane on elderly patients undergoing radical resection for gallbladder cancer." Tropical Journal of Pharmaceutical Research 21, no. 3 (2022): 655–63. http://dx.doi.org/10.4314/tjpr.v21i3.28.

Full text

Abstract:

Purpose: To determine the efficacy of dexmedetomidine (DEX) plus either isoflurane or sevoflurane, in elderly gallbladder cancer patients given radical resection. Methods: A total of 278 elderly patients assessed for eligibility and scheduled for radical gallbladder cancer resection in Hunan Cancer Hospital, Changsha, China were recruited. They were randomly assigned at a ratio of 1:1 to receive either DEX plus isoflurane or DEX plus sevoflurane. These two groups were compared with respect to immune functions (CD3+, CD 4+, CD 8+, and CD4+/CD8+ T cells); inflammatory factors, and cognitive func

APA, Harvard, Vancouver, ISO, and other styles

42

Tanabe, Norikazu, Issei Saeki, Yuki Aibe, et al. "Early Prediction of Response Focused on Tumor Markers in Atezolizumab plus Bevacizumab Therapy for Hepatocellular Carcinoma." Cancers 15, no. 11 (2023): 2927. http://dx.doi.org/10.3390/cancers15112927.

Full text

Abstract:

Despite the promising efficacy of atezolizumab plus bevacizumab (atezo/bev), some patients with unresectable hepatocellular carcinoma (HCC) experience disease progression. This retrospective study, which included 154 patients, aimed to evaluate predictors of treatment efficacy of atezo/bev for unresectable HCC. Factors associated with treatment response were examined, focusing on tumor markers. In the high-alpha-fetoprotein (AFP) group (baseline AFP ≥ 20 ng/mL), a decrease in AFP level > 30% was an independent predictor of objective response (odds ratio, 5.517; p = 0.0032). In the low-AFP g

APA, Harvard, Vancouver, ISO, and other styles

43

Heymach, John V., Bruce E. Johnson, Diane Prager, et al. "Randomized, Placebo-Controlled Phase II Study of Vandetanib Plus Docetaxel in Previously Treated Non–Small-Cell Lung Cancer." Journal of Clinical Oncology 25, no. 27 (2007): 4270–77. http://dx.doi.org/10.1200/jco.2006.10.5122.

Full text

Abstract:

Purpose Vandetanib is a once-daily oral inhibitor of vascular endothelial growth factor receptor-2 and epidermal growth factor receptor kinase activity. The activity of vandetanib plus docetaxel was assessed in patients with previously treated non–small-cell lung cancer (NSCLC). Patients and Methods This two-part study comprised an open-label run-in phase and a double-blind randomized phase. Eligible patients had locally advanced or metastatic (stage IIIB/IV) NSCLC after failure of first-line platinum-based chemotherapy. The primary objective of the randomized phase was to prolong progression-

APA, Harvard, Vancouver, ISO, and other styles

44

Xiong, Wei, Lixiu Zhu, Guoqiang Xu, et al. "Comparison of first-line treatments for recurrent or metastatic nasopharyngeal carcinoma based on phase 3 randomized clinical trials." Journal of Clinical Oncology 41, no. 16_suppl (2023): e18012-e18012. http://dx.doi.org/10.1200/jco.2023.41.16_suppl.e18012.

Full text

Abstract:

e18012 Background: Guidelines recommend platinum-based chemotherapy as first-line treatment for recurrent or metastatic nasopharyngeal carcinoma (R/M NPC) patients. There are a variety of available combination treatment options, however, there is lack of research evaluating their advantages and disadvantages. Therefore, this study aims to compare the efficacy and adverse events (AEs) of the first-line treatment for R/M NPC. Methods: PubMed, EMBASE, Web of Science, and the Cochrane Library were systematically searched for phase 3 randomized clinical trials (RCTs) in which two first-line treatme

APA, Harvard, Vancouver, ISO, and other styles

45

Wang, Xiaodong. "NeoTACE: A multicenter, randomized study evaluating the efficacy and safety of neoadjuvant HAIC for TACE plus donafenib in BCLC B stage hepatocellular carcinoma outside of up-to-seven." Journal of Clinical Oncology 41, no. 16_suppl (2023): TPS4186. http://dx.doi.org/10.1200/jco.2023.41.16_suppl.tps4186.

Full text

Abstract:

TPS4186 Background: Transarterial chemoembolization (TACE) is standard treatment for hepatocellular carcinoma (HCC) patients in BCLC B stage, while a number of studies demonstrated compromised effect of TACE for patients with large HCC or tumor burden outside of up-to-7. Recently, two phase 3 studies showed the survival benefit of Hepatic arterial infusion chemotherapy (HAIC) for large HCC and as neoadjuvant treatment for HCC outside of Milan criteria. A Phase 3 study also showed the survival benefit of donafenib for unresectable HCC compared with sorafenib. Here, we propose a prospective rand

APA, Harvard, Vancouver, ISO, and other styles

46

Baselga, José, Patricia Gómez, Richard Greil, et al. "Randomized Phase II Study of the Anti–Epidermal Growth Factor Receptor Monoclonal Antibody Cetuximab With Cisplatin Versus Cisplatin Alone in Patients With Metastatic Triple-Negative Breast Cancer." Journal of Clinical Oncology 31, no. 20 (2013): 2586–92. http://dx.doi.org/10.1200/jco.2012.46.2408.

Full text

Abstract:

Purpose Epidermal growth factor receptor is overexpressed in metastatic triple-negative breast cancers (mTNBCs), an aggressive subtype of breast cancer. Our randomized phase II study investigated cisplatin with or without cetuximab in this setting. Patients and Methods Patients who had received no more than one previous chemotherapy regimen were randomly assigned on a 2:1 schedule to receive no more than six cycles of cisplatin plus cetuximab or cisplatin alone. Patients receiving cisplatin alone could switch to cisplatin plus cetuximab or cetuximab alone on disease progression. The primary en

APA, Harvard, Vancouver, ISO, and other styles

47

Tsai, Yu-Chen, Hsiao-Ling Chen, Tai-Huang Lee, et al. "Salvage Therapy for Relapsed Malignant Pleural Mesothelioma: A Systematic Review and Network Meta-Analysis." Cancers 14, no. 1 (2021): 182. http://dx.doi.org/10.3390/cancers14010182.

Full text

Abstract:

Patients with malignant pleural mesothelioma (MPM) have very poor prognoses, and pemetrexed plus platinum is the standard first-line therapy. However, the second-line therapy for relapsed MPM remains controversial. A comprehensive search was performed to identify randomized controlled trials (RCTs) evaluating various second-line regimens in patients with relapsed MPM. Indirect comparisons of overall survival (OS) and progression-free survival (PFS) were performed using network meta-analysis. Surface under the cumulative ranking curve (SUCRA) values were used to rank the included treatments acc

APA, Harvard, Vancouver, ISO, and other styles

48

De Vita, Ferdinando, Christophe Borg, Gabriella Farina, et al. "Ramucirumab and paclitaxel in patients with gastric cancer and prior trastuzumab: subgroup analysis from RAINBOW study." Future Oncology 15, no. 23 (2019): 2723–31. http://dx.doi.org/10.2217/fon-2019-0243.

Full text

Abstract:

Aim: This subgroup analysis of the RAINBOW study evaluated the efficacy and safety of ramucirumab in patients with gastric cancer/gastroesophageal junction adenocarcinoma who received prior trastuzumab therapy. Patients & methods: Of adult patients enrolled in the RAINBOW study, 39 had received prior trastuzumab therapy. Of these, 20 patients were treated with ramucirumab plus paclitaxel and 19 patients with placebo plus paclitaxel within the RAINBOW trial. Results: Overall survival was longer with ramucirumab plus paclitaxel (11.4 months; 95% CI: 7.0–17.9) versus placebo plus paclitaxel (

APA, Harvard, Vancouver, ISO, and other styles

49

Izuishi, Kunihiko, and Hirohito Mori. "Recent Strategies for Treating Stage IV Gastric Cancer: Roles of Palliative Gastrectomy, Chemotherapy, and Radiotherapy." Journal of Gastrointestinal and Liver Diseases 25, no. 1 (2016): 87–94. http://dx.doi.org/10.15403/jgld.2014.1121.251.rv2.

Full text

Abstract:

Recently, many strategies have been reported for the effective treatment of gastric cancer. However, the strategy for treating stage IV gastric cancer remains controversial. Conducting a prospective phase III study in stage IV cancer patients is difficult because of heterogeneous performance status, age, and degree of cancer metastasis or extension. Due to poor prognosis, the variance in physical status, and severe symptoms, it is important to determine the optimal strategy for treating each individual stage IV patient. In the past decade, many reports have addressed topics related to stage IV

APA, Harvard, Vancouver, ISO, and other styles

50

De Mello, Ramon Andrade, Emili Ayoub, Pedro Castelo-Branco, et al. "Comparative cost-effectiveness analysis of avelumab plus axitinib versus pembrolizumab plus axitinib, ipilimumab plus nivolumab, and sunitnib for advanced renal cell carcinoma in the U.K. Perspective." Journal of Clinical Oncology 38, no. 6_suppl (2020): 689. http://dx.doi.org/10.1200/jco.2020.38.6_suppl.689.

Full text

Abstract:

689 Background: Avelulmab plus axitinib showed to improve clinical outcomes for patients with advanced renal cell carcinoma (aRCC) in the JAVELIN RENAL 101 trial. Several other immunocheckpints inihibitos (ICIs) options acquired a main role in the aRCC treatment, such as nivolumab plus ipilimumab and pembrolizumab plus axitinib. Our aim is to evaluate the cost effectiveness of avelumab/axitinib versus other FDA approved options for previously untreated patients with aRCC. Methods: A Markov model was used to estimate the costs and health outcomes of treatment of aRCC with sunitinib, or avelumab

APA, Harvard, Vancouver, ISO, and other styles

We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!